Carbadox
(Synonyms: 卡巴多) 目录号 : GC16295
A broad-spectrum antimicrobial agent
Cas No.:6804-07-5
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Carbadox is a quinoxaline-di-N-oxide antibiotic compound which is widely fed to nursery-age pigs to control enteric diseases and improve feed efficiency.
The results of MTT assay demonstrate a dose-dependent decrease in mitochondrial activity in Vero cells at all concentrations of Carbadox. Treatment with Carbadox at the highest concentration of 160 μg/mL results in cell viability down to only 12%. Cells following Carbadox treatment show a dose-dependent increase of the DNA migration (p
Alpha diversities (Shannon diversity, Heips evenness, and inverse Simpson indices) of samples from medicated piglets compare to non-medicated piglets are significantly different at 2, 3, and 4 days after continuous Carbadox, but not different in either late Carbadox or at any time during the withdrawal period. Analysis of the community structure of bacteria in animals shows significant differences at days 3 and 4 of early Carbadox treatment ([R=0.32, p=0.015] and [R=0.54, p=0.003], respectively), but not before starting antibiotic treatment (p=0.82). No significant differences in E. coli colony forming units (CFUs) are observed during the Carbadox-treatment period of the study or late in the withdrawal period. E. coli CFUs are significantly different between the medicated and non-medicated groups on day 2 after the withdrawal of Carbadox[2].
References:
[1]. Chen Q, et al. Investigation of the genotoxicity of quinocetone, carbadox and olaquindox in vitro using Vero cells. Food Chem Toxicol. 2009 Feb;47(2):328-34.
[2]. Looft T, et al. Carbadox has both temporary and lasting effects on the swine gut microbiota. Front Microbiol. 2014 Jun 10;5:276.
Cell experiment: | Exponentially growing Vero cells are seeded at 104 cells/well density in 96 microplates and exposed to various concentrations of Carbadox (5, 10, 20, 40, 80, 160, 210, 260, 310 and 360 μg/mL). Cells incubated with the same concentration DMSO are used as a control. After 4 h or 24 h, each well is added 100 μL MTT solution (200 μg/mL) followed incubation for 4 h at 37 °C, and the medium containing MTT is removed. The formazan crystals in the viable cells are solubilized with 100 μL DMSO and the absorbance at 570 nm of each well is read using a microplate reader. All experiments are performed at least 3 times, with 6 wells for each concentration of Carbadox (n=6 per experiment). Final results are the average of three independent experiments. The cell viability is calculated as follows: OD of experimental group/(OD of control group-OD of blank group)×100%. The data are presented as means±SE[1]. |
Animal experiment: | At 3 weeks of age, 12 piglets from 2 litters are divided into two rooms of six pigs each, with equal representation of littermates and gender. All pigs are fed a standard starter diet ad libitum for 3 weeks, after which six control pigs continue to receive non-medicated feed while the other group receives feed containing Carbadox (50 g/ton). After 21 days of continuous feed with or without Carbadox, all pigs (60 days old) are switched to a non-medicated maintenance diet. Feces are collected from each pig at multiple times before, during, and after antibiotic withdrawal[2]. |
References: [1]. Chen Q, et al. Investigation of the genotoxicity of quinocetone, carbadox and olaquindox in vitro using Vero cells. Food Chem Toxicol. 2009 Feb;47(2):328-34. | |
| Cas No. | 6804-07-5 | SDF | |
| 别名 | 卡巴多 | ||
| 化学名 | methyl N-[(E)-(1-hydroxy-4-oxidoquinoxalin-4-ium-2-ylidene)methyl]iminocarbamate | ||
| Canonical SMILES | COC(=O)N=NC=C1C=[N+](C2=CC=CC=C2N1O)[O-] | ||
| 分子式 | C11H10N4O4 | 分子量 | 262.22 |
| 溶解度 | 1 M NaOH: 50 mg/ml,Water: slightly | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 3.8136 mL | 19.068 mL | 38.1359 mL |
| 5 mM | 0.7627 mL | 3.8136 mL | 7.6272 mL |
| 10 mM | 0.3814 mL | 1.9068 mL | 3.8136 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet